Aug 16 (Reuters) - Seagen said on Wednesday its cancer therapy in combination with Roche's Kadcyla helped control disease progression in a late-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
4,338 INR | +0.78% | +3.03% | 2.36B | ||
2,728 PTS | +0.54% | -0.01% | - | ||
225.1 CHF | +1.26% | +3.59% | 198B | ||
1st Jan change | Capi. | |
---|---|---|
+17.96% | 47.02B | |
+48.77% | 41.86B | |
+1.17% | 41.76B | |
-4.27% | 28.8B | |
+11.42% | 26.05B | |
-21.39% | 19.15B | |
+4.86% | 12.55B | |
+27.29% | 12.34B | |
-3.50% | 11.82B |